logo
Plus   Neg
Share
Email

Stock Alert: Sorrento Therapeutics Uptick Continues

Shares of Sorrento Therapeutics, Inc. (SRNE) are currently gaining 17% on Friday morning, continuing its upward momentum from Thursday.

The biotech company on Wednesday had announced the launch of a rapid diagnostic saliva COVID-19 test that reveals results in 30 minutes.

SRNE is currently trading at $10.03, up $1.48 or 17.31%, on the Nasdaq.

The company said it licensed the Covid-19 from Columbia University that can provide highly accurate results in thirty minutes using only a person's saliva.

Developed by the team at Columbia University Irving Medical Center (CUIMC), initial clinical studies have been extremely promising for both specificity and sensitivity.
Sorrento plans to market the product under the name COVI-TRACE.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT